- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 21.10.24 | BB Biotech - A key milestone with significance for the sector | 896 | BB Biotech (BION) invests in innovative, rapidly expanding biotech companies. BION's portfolio company Wave Life Sciences (Wave) recently announced a significant milestone in the field of genetic medicine:... ► Artikel lesen | ||
| 17.10.24 | Primary Health Properties - Highlighting organic and investment-led growth | 313 | Primary Health Properties (PHP) has issued a Q324 trading update alongside its capital markets presentation. The presentation focused on the significant opportunities for growth that PHP has identified... ► Artikel lesen | ||
| 17.10.24 | Esker - On track to meet FY24 guidance | 260 | Esker made further good progress in Q324, with constant currency (cc) revenue growth of 17% y-o-y in Q324 and 14% for 9M24. Guidance was maintained for FY24; we have revised up our forecasts with revenue... ► Artikel lesen | ||
| 16.10.24 | Alkane Resources - Seamlessly shifting to Roswell | 272 | On 14 October, Alkane released its Q125 quarterly activities report, showing almost all of its operating parameters in line with both guidance and our expectations for the full year. The exceptions... ► Artikel lesen | ||
| 16.10.24 | discoverIE Group - Orders stabilising, EPS & margin targets on track | 238 | discoverIE's H125 trading update confirmed that underlying earnings expectations for FY25 are unchanged. Destocking by industrial customers reduced in H125, with some now starting to place orders, resulting... ► Artikel lesen | ||
| 15.10.24 | Actinogen Medical - A$11.1m capital raise completed | 337 | Actinogen Medical announced the successful completion of its A$3.0m share purchase plan (SPP), which closed 1.3x oversubscribed. With its previously disclosed A$8.1m share placement, total funds from... ► Artikel lesen | ||
| 15.10.24 | Calgro M3 - Earnings underpinned by gross profit margin | 291 | Calgro M3's core business is integrated residential housing development and memorial parks. In the six months to August 2024, the company posted a 28.5% increase in EPS to 101.4 cents, which also represented... ► Artikel lesen | ||
| 15.10.24 | S&U - The time to look ahead | 288 | In line with earlier guidance, S&U reported H125 PBT of £12.8m, a significant decline versus H124 but an improvement versus H224. Customer repayment collections and earnings in the motor finance business... ► Artikel lesen | ||
| 14.10.24 | The Diverse Income Trust - Could be the time for UK equities to shine | 210 | The Diverse Income Trust (DIVI) is a member of the 18-strong AIC UK Equity Income sector. It has a differentiated multi-cap income strategy and therefore its performance can differ meaningfully from... ► Artikel lesen | ||
| 14.10.24 | Altron - Strong earnings growth in H125 | 332 | Altron has provided an H125 trading update pointing to a more than doubling of headline EPS from continuing operations and an even larger increase in reported EPS. Having restated comparatives to reflect... ► Artikel lesen | ||
| 14.10.24 | JPMorgan European Discovery Trust - European small caps: On the verge of a rebound? | 468 | JPMorgan European Discovery Trust (JEDT) invests in European small-cap companies (excluding UK). European small caps have outperformed most other markets over the long term, although they underperformed... ► Artikel lesen | ||
| 14.10.24 | Argent Biopharma - Valuation report | 336 | We value Argent at an un-risked net present value (NPV) of US$1.1bn. Adjusting for the company's specified probabilities of success (PoS) for its three clinical programmes gives a risk-adjusted NPV... ► Artikel lesen | ||
| 14.10.24 | 1Spatial - Contract momentum underpins growth prospects | 229 | 1Spatial's H1 results showed a continued improvement in the quality of revenues, while recent deal flow provides good support for our expectation of faster growth and margin expansion from H2. Most... ► Artikel lesen | ||
| 11.10.24 | Basilea Pharmaceutica - Milestone march continues for Cresemba | 428 | Basilea Pharmaceutica has reported another US$1.25m milestone payment from its partner Pfizer in Asia-Pacific and China, triggered by Cresemba sales in this region crossing a pre-defined threshold.... ► Artikel lesen | ||
| 11.10.24 | Sareum Holdings - New funding extends runway to Phase II | 335 | Sareum Holdings has announced the completion of a £2.4m private placement and receipt of another A$1.9m (c £1m) in R&D tax credits from Australian authorities, related to the Phase I clinical trial... ► Artikel lesen | ||
| 11.10.24 | Ocean Wilsons Holdings Limited - Confirmation of interest in Wilson Sons holding | 319 | Ocean Wilsons Holdings' (OCN's) H124 results showed good growth, reflecting a strong performance from Wilson Sons and a positive performance from the investment portfolio (OWIL). While the strategic... ► Artikel lesen | ||
| 11.10.24 | IP Group - Record exit underpinning the NAV | 258 | IP Group's realisation activity has picked up notably in the months leading up to the company's interim results publication in September, encouraging the company to increase the current buyback programme... ► Artikel lesen | ||
| 10.10.24 | Centaur Media - Tough trading backdrop persists in H2 | 220 | Centaur's management has reframed its outlook for the remainder of FY24 to reflect the continuing difficult trading environment for XEIM, where its clients (predominantly major global brand owners)... ► Artikel lesen | ||
| 10.10.24 | Baillie Gifford US Growth Trust - Seeking tomorrow's mega caps | 232 | The managers of Baillie Gifford US Growth Trust (USA), Gary Robinson and Kirsty Gibson, invest in exceptional US businesses with the potential to grow substantially faster than the market and deliver... ► Artikel lesen | ||
| 10.10.24 | MoneyHero - Investing for the long term | 256 | MoneyHero's Q224 results reflect management's strategy of growing market share in its core geographies, as it invests in advertising, customer rewards and its platforms. Approved application conversion... ► Artikel lesen | ||
| 09.10.24 | UIL - Announcement of 2028 privatisation plans | 144 | On 8 October 2024, UIL Limited (UIL) announced plans to take the company private after the redemption of the 2028 zero dividend preference (ZDP) shares. UIL's board has decided that despite holding... ► Artikel lesen | ||
| 09.10.24 | OSE Immunotherapeutics - Riding the H124 tailwinds | 328 | OSE Immunotherapeutics has reported its results for H124, a standout period for the company's development pipeline, with the momentum carrying into H224. The first half of the year rewarded the company... ► Artikel lesen | ||
| 09.10.24 | 1Spatial - Federal-level win in the US | 256 | 1Spatial's momentum in the US has continued, with the company securing a $1.4m deal with the United States Forest Service (USFS). This is a new Federal government-level deal for the business, building... ► Artikel lesen | ||
| 08.10.24 | IRLAB Therapeutics - IRL757 progress prompts $2.5m milestone payment | 270 | IRLAB Therapeutics has announced that it will receive a $2.5m milestone payment from the McQuade Center for Strategic Research and Development (MSRD), prompted by the dosing of the first participant... ► Artikel lesen | ||
| 08.10.24 | CI Games - Strategic roadmap to 2028 | 314 | CI Games outlined its updated strategy to 2028 at its H124 results. The strategy focuses on greater efficiencies to produce higher-quality games, while growing its audience base, and includes three... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
